Moreover, a novel CXCR4 antagonist, BL-8040 or motixafortide, in combination with immuno- and chemotherapy, increased anti-tumor immune responses in pancreatic cancer patients [275]. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.